Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Marker Therapeutics, Inc. Director's Dealing 2021

Feb 24, 2021

35150_dirs_2021-02-24_ff6560ac-2ee7-40f2-b232-78542c5ac948.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2020-02-15

Reporting Person: Leen Ann M. (Chief Scientific Officer)